harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Company profile
Ticker
HBIO
Exchange
Website
CEO
James W. Green
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Biochrom Limited • Biochrom US, Inc. • CMA Microdialysis Ab • Data Sciences International, Inc. • Data Sciences (UK) Mn, Ltd. • Data Sciences GmbH • DSI (Shanghai) Trading Co Ltd. • Harvard Bioscience (Shanghai) Co. Ltd. • Hugo Sachs Elektronik - Harvard Apparatus GmbH • Multichannel Systems MCS GmbH ...
IRS number
43306140
HBIO stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
29 May 24
8-K
Submission of Matters to a Vote of Security Holders
14 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Harvard Bioscience Announces First Quarter 2024 Financial Results
7 May 24
ARS
2023 FY
Annual report to shareholders
3 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
8-K
Entry into a Material Definitive Agreement
3 Apr 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
Transcripts
HBIO
Earnings call transcript
2024 Q1
7 May 24
HBIO
Earnings call transcript
2023 Q4
7 Mar 24
HBIO
Earnings call transcript
2023 Q3
7 Nov 23
HBIO
Earnings call transcript
2023 Q2
8 Aug 23
HBIO
Earnings call transcript
2023 Q2
8 Aug 23
HBIO
Earnings call transcript
2023 Q1
25 Apr 23
HBIO
Earnings call transcript
2022 Q4
9 Mar 23
HBIO
Earnings call transcript
2022 Q3
8 Nov 22
HBIO
Earnings call transcript
2022 Q2
7 Aug 22
HBIO
Earnings call transcript
2022 Q1
4 May 22
Latest ownership filings
4
BERTRAND LOY
23 May 24
4
Thomas W Loewald
23 May 24
4
Katherine A. Eade
23 May 24
4
ALAN I EDRICK
23 May 24
SC 13G
Leviticus Partners LP
19 Mar 24
4
Jennifer Cote
7 Mar 24
4
James W Green
7 Mar 24
SC 13G/A
Harvey Partners, LLC
14 Feb 24
SC 13G/A
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
14 Feb 24
SC 13G/A
B. Riley Asset Management, LLC
14 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.26 mm | 4.26 mm | 4.26 mm | 4.26 mm | 4.26 mm | 4.26 mm |
Cash burn (monthly) | 9.33 k | (no burn) | 1.49 mm | 718.17 k | (no burn) | (no burn) |
Cash used (since last report) | 19.30 k | n/a | 3.09 mm | 1.48 mm | n/a | n/a |
Cash remaining | 4.24 mm | n/a | 1.16 mm | 2.77 mm | n/a | n/a |
Runway (months of cash) | 453.8 | n/a | 0.8 | 3.9 | n/a | n/a |
Institutional ownership, Q4 2023
0.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 90 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 2.06 bn |
Total shares | 384.66 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Pasadena Private Wealth | 172.49 k | $922.80 mm |
Riverwater Partners | 81.71 k | $437.12 mm |
Assenagon Asset Management | 77.48 k | $414.53 mm |
Legato Capital Management | 32.02 k | $171.29 mm |
Mirae Asset Global Investments | 20.97 k | $112.21 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 May 24 | Eade Katherine A. | Common Stock | Grant | Acquire A | No | No | 0 | 45,872 | 0.00 | 311,126 |
21 May 24 | Loewald Thomas W | Common Stock | Grant | Acquire A | No | No | 0 | 45,872 | 0.00 | 295,311 |
21 May 24 | Edrick Alan I | Common Stock | Grant | Acquire A | No | No | 0 | 45,872 | 0.00 | 273,911 |
21 May 24 | Bertrand Loy | Common Stock | Grant | Acquire A | No | No | 0 | 56,575 | 0.00 | 56,575 |
29 Dec 23 | Jennifer Cote | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 2,631 | 14.08 k | 107,058 |
29 Dec 23 | Jennifer Cote | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 3,279 | 17.54 k | 109,689 |
News
Harvard Bioscience Continues To Expect 2024 Gross Margin Of Approximately 60% And Adjusted EBITDA Margin In The Mid-teens
7 May 24
Harvard Bioscience Q1 Adj $0.02, Inline, Sales $24.51M Miss $25.79M Estimate
7 May 24
Harvard Bioscience Q4 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.15M Miss $29.11M Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
A Preview Of Harvard Bioscience's Earnings
6 Mar 24
Press releases
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
23 May 24
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
16 May 24
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
29 Apr 24
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
7 Mar 24